SCHEMBL6987139

SCHEMBL6987139

O=Cc1cccc(-c2ccco2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
KDM4E B2RXH2 8/20 0.47
MAPT P10636 5/20 0.44
HSD17B10 Q99714 5/20 0.44
POLB P06746 4/20 0.44
PKM P14618 3/20 0.44
BLM P54132 3/20 0.44
HPGD P15428 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
MEN1 O00255 2/20 0.44
ALOX15 P16050 2/20 0.44
CASP1 P29466 2/20 0.44
PTPN7 P35236 2/20 0.44
RECQL P46063 2/20 0.44
CASP7 P55210 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954228 1.00 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTHSD17B10POLB
SCHEMBL13556441 0.82 KDM4E (0.46) ALDH1A1KDM4EMAPTHSD17B10POLB
SCHEMBL3060017 0.80 KDM4E (0.58) ALDH1A1KDM4EMAPTHSD17B10POLB
SCHEMBL4141663 0.79 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHSD17B10POLB
SCHEMBL29476108 0.78 CCR1 (0.48) ALDH1A1KDM4ETDP1L3MBTL1MEN1
SCHEMBL2151538 0.78 CCR1 (0.48) ALDH1A1KDM4ETDP1L3MBTL1MEN1
SCHEMBL6978343 0.76 ROCK2 (0.51) ALDH1A1KDM4EPOLBPKMMEN1
SCHEMBL2162155 0.75 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTHSD17B10POLB
SCHEMBL29953306 0.74 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTHSD17B10POLB
SCHEMBL9236747 0.72 KDM4E (0.50) ALDH1A1KDM4EMAPTHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336743-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2019-07-02 US disclosed
US-20170247367-A1 AMINOPYRIMIDINE KINASE INHIBITORS P2K DYNAMICS INC. 2017-08-31 US disclosed
EP-2699569-B1 AMINOPYRIMIDINE KINASE INHIBITORS JASCO PHARMACEUTICALS LLC (US) 2017-08-30 EP disclosed
EP-2699569-B1 AMINOPYRIMIDINE KINASE INHIBITORS JASCO PHARMACEUTICALS LLC (US) 2017-08-30 EP disclosed
US-9629840-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2017-04-25 US disclosed
EP-2776432-B1 AMINOPYRIMIDINE KINASE INHIBITORS JASCO PHARMACEUTICALS LLC (US) 2017-03-29 EP disclosed
US-20150202205-A1 AMINOPYRIMIDINE KINASE INHIBITORS P2K DYNAMICS INC. 2015-07-23 US disclosed
US-8927525-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2015-01-06 US disclosed
US-8901145-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2014-12-02 US disclosed
US-8901145-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2014-12-02 US disclosed
WO-2013066684-A1 AMINOPYRIMIDINE KINASE INHIBITORS Jasco Pharmaceuticals, LLC (US) 2013-05-10 WO disclosed
WO-2012145617-A2 AMINOPYRIMIDINE KINASE INHIBITORS Jasco Pharmaceuticals, LLC (US) 2012-10-26 WO disclosed
WO-2012145617-A2 AMINOPYRIMIDINE KINASE INHIBITORS Jasco Pharmaceuticals, LLC (US) 2012-10-26 WO disclosed
US-20120270892-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2012-10-25 US disclosed
US-20120270892-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2012-10-25 US disclosed
US-20120270892-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2012-10-25 US disclosed
EP-0946546-B1 PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE PF MEDICAMENT (FR) 2003-06-25 EP disclosed
US-6020345-A Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine PIERRE FABRE MEDICAMENT (FR) 2000-02-01 US disclosed
EP-0946546-A1 PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE PIERRE FABRE MEDICAMENT (FR) 1999-10-06 EP disclosed
WO-1998022459-A1 PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE PIERRE FABRE MEDICAMENT (FR) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247367-A1 AMINOPYRIMIDINE KINASE INHIBITORS PIM1, PIM2, PIM3 ALDH1A1 3087/4885KDM4E 1116/4885MAPT 1815/4885
US-20120270892-A1 Aminopyrimidine Kinase Inhibitors PIM1, PIM2, PIM3 ALDH1A1 3305/4885KDM4E 1380/4885MAPT 1335/4885
US-20150202205-A1 AMINOPYRIMIDINE KINASE INHIBITORS PIM1, PIM2, PIM3 ALDH1A1 2942/4885KDM4E 1150/4885MAPT 1780/4885
US-10336743-B2 Aminopyrimidine kinase inhibitors PIM1, PIM2, PIM3 ALDH1A1 2942/4885KDM4E 1150/4885MAPT 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.